The report noted that in 2013, there was a sharp decline in the D.E.A.’s issuance of immediate suspension orders, which it called the agency’s “strongest enforcement tool” because the orders can stop companies from distributing drugs.
The agency has attributed that decline to the end of two major operations in 2012, and it said in its statement on Tuesday that it had removed about 900 registrations — which allow entities to distribute or prescribe controlled substances — every year for the past eight years.
Andrew Kolodny, a director of opioid policy research at the Heller School for Social Policy and Management at Brandeis University who also testifies as an expert for government plaintiffs against pharmaceutical companies, said the review did not address the problems at the root of the opioid crisis — such as over-prescription of painkillers — because it was narrowly focused on the D.E.A.
“When you read the report, what you really don’t get out of it is that in almost every way in which the D.E.A. failed — except for the fact that they could have managed their data better — you have pharmaceutical industry and distributor industry influence,” he said.
The inspector general’s review comes at a critical moment in federal opioid litigation: A consolidation of nearly 2,300 cases from cities, counties and tribes nationwide seeking reparations for the epidemic.
The first trial, set to begin in Cleveland this month, pits two hard-hit Ohio counties against an array of drug manufacturers, distributors and retailers, which the plaintiffs blame for the crisis. But in laying substantial blame at the feet of the D.E.A., the inspector general has, in effect, given the drug industry defendants a powerful retort on the eve of trial.
Jan Hoffman contributed reporting.